Key Takeaways:
CSPC Pharmaceutical Group Ltd. received market launch approval from China's National Medical Products Administration for its first biosimilar of the blockbuster immunology drug Stelara.
The self-developed ustekinumab injection, to be marketed as Enyike, is a copy of Johnson & Johnson's Stelara, which was first approved for use in China in 2017. The originator drug is used for treating conditions including adult plaque psoriasis and Crohn's disease.
The approval for Enyike comes as several drugmakers are launching Stelara biosimilars globally. In a separate announcement, South Korea's Samsung Bioepis said it launched its own ustekinumab biosimilar in Japan under a partnership with Nipro Corporation.
This approval positions CSPC Pharma to challenge the originator drug for a share of the multi-billion dollar immunology market in China. The introduction of a lower-cost biosimilar is expected to create a significant new revenue stream for the company.
The successful development and approval of Enyike strengthens CSPC's specialty drug pipeline. Investors will be watching the initial market uptake and pricing strategy in the second half of 2026 to gauge its long-term revenue potential against the established brand.
This article is for informational purposes only and does not constitute investment advice.
